SLC2A4 and cancer: Emerging evidence suggests that pharmacological inhibition of Solute carrier family-2-member-4-gene (Slc2a4), which encodes glucose transporter 4 protein (GLUT4), is an attractive therapeutic target for the development of a novel drug candidate for the treatment of cancer [12,13,14].